By David Bautz, PhD NASDAQ:SNGX READ THE FULL CERC RESEARCH REPORT Business Update Topline Results for SGX942 in 4Q20 Soligenix, Inc. (NASDAQ:SNGX) is currently conducting the Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) trial of SGX942 in the treatment of oral mucositis (OM) in… Read More..
GIG HARBOR, Wash., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes®,” or the “Company”), (NASDAQ:HCDI), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced consolidated financial results for the third quarter ended September 30,… Read More..
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in the following conferences during the month of November: 2020 Virtual Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day One-on-one meetings Monday, November 16, 2020 Virtual Fall Investor… Read More..